Table 2.

Univariable and multivariable Cox regression models for development of CAPA within 90 days

Variable	Univariable hazard ratio	95% CI	p value
Demographic variables
Age (per 5 years)	1.18	1.08–1.28	<0.001
Female gender	0.68	0.42–1.09	0.117
Study centre	1.02	0.99–1.05	0.071
Coexisting conditions
Number of coexisting conditions	0.92	0.76–1.10	0.380
Obesity	0.89	0.54–1.44	0.638
Active malignant disease	1.56	0.81–3.00	0.181
Solid organ transplantation	2.20	0.90–5.42	0.084
Cardiovascular disease	1.20	0.81–1.78	0.348
Pulmonary disease	1.42	0.89–2.24	0.133
Diabetes	1.12	0.73–1.73	0.605
History of smoking	1.36	0.76–2.44	0.293
Maximum ventilation
vvECMO (included in any invasive respiratory support)	0.80	0.37–1.70	0.547
Invasive ventilation (included in any invasive respiratory support)	2.53	1.53–4.17	<0.001
Non-invasive ventilation	0.08	0.02–0.33	<0.001
Any invasive respiratory support	2.93	1.60–5.35	<0.001
Specific medication
Glucocorticoids	1.01	0.68–1.50	0.962
Tocilizumab	2.34	1.35–4.06	0.002
Azithromycin	0.63	0.33–1.21	0.167
Variable	Multivariable hazard ratio	95% CI	p value
Age per year	1.04	1.02–1.06	<0.001
Any invasive respiratory support	3.40	1.84–6.25	<0.001
Tocilizumab	2.45	1.41–4.25	<0.001

Abbreviations: CAPA, COVID-19-associated pulmonary aspergillosis; vvECMO, veno-venous extracorporeal membrane oxygenation.